Federal agencies (FDA/CDC) identified a “moderately elevated” stroke risk in seniors post-Pfizer bivalent booster as early as October 2022—but never warned the public, despite 7 internal analyses confirming the signal. Officials softened language in internal documents, changing “moderately elevated…